Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Sys⦠read more
Healthcare
Medical Devices
26 years
USD
Exclusive to Premium users
$1.24
Price-2.36%
-$0.03
$237.707m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$192.510m
-
1y CAGR-
3y CAGR-
5y CAGR-$18.879m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.10
-
1y CAGR-
3y CAGR-
5y CAGR$56.170m
$213.071m
Assets$156.901m
Liabilities$98.898m
Debt46.4%
-11.5x
Debt to EBITDA$3.423m
-
1y CAGR-
3y CAGR-
5y CAGR